<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850327</url>
  </required_header>
  <id_info>
    <org_study_id>RD020</org_study_id>
    <nct_id>NCT03850327</nct_id>
  </id_info>
  <brief_title>BIO|CONCEPT.BIOMONITOR III</brief_title>
  <official_title>BIO|CONCEPT.BIOMONITOR III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to confirm the safety and efficacy of the BIOMONITOR III
      system. Furthermore, the insertion procedure, the use and handling of the incision and
      insertion tools and the sensing quality of the BIOMONITOR III will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 month</time_frame>
    <description>(procedure / device related)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>R-wave amplitude</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insertion procedure of the BIOMONITOR III by using the incision and insertion tools</measure>
    <time_frame>At the day of insertion of the BIOMONITOR III</time_frame>
    <description>Assessment of insertion procedure by using a questionaire about handling and time record.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Syncope</condition>
  <condition>Tachyarrhythmia</condition>
  <arm_group>
    <arm_group_label>BIOMONITOR III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIOMONITOR III</intervention_name>
    <description>Patients with ICM indication receive a third-generation implantable cardiac monitor</description>
    <arm_group_label>BIOMONITOR III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is at high risk of developing a clinically important cardiac arrhythmia; or
             Patient is undergoing investigation for symptoms such as palpitations, pre-syncope or
             syncope, that are suggestive of an underlying cardiac arrhythmia; or Patient is
             undergoing investigation for the detection of atrial fibrillation following
             cryptogenic stroke; or Patient is planned for AF ablative procedure or has already
             undergone an AF ablative procedure.

          -  Patient is able to understand the nature of study and has provided written informed
             consent.

          -  Patient is willing and able to perform all follow up visits at the study site.

          -  Patient is willing and able to use the CardioMessenger and accepts the BIOTRONIK Home
             Monitoring concept.

        Exclusion Criteria:

          -  Patients implanted with ICD or pacemaker.

          -  Patient is pregnant or breast feeding.

          -  Patient is less than 18 years old.

          -  Patient is participating in another interventional clinical investigation

          -  PatientÂ´s life-expectancy is less than 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier van den Brink, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred Hospital, Melbourne, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HeartCare Partners - Wesley Testing</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundaberg Cardiology</name>
      <address>
        <city>Bundaberg</city>
        <state>Queensland</state>
        <zip>4670</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HeartCare Victoria - Doncaster</name>
      <address>
        <city>Balwyn</city>
        <state>Victoria</state>
        <zip>3103</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Canberra Hospital</name>
      <address>
        <city>Canberra</city>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Implantable Cardiac Monitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syncope</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

